Pauline Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pauline Kim has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Dong Moon Shin
Winship Cancer Institute, Emory University, Atlanta, Georgia
2 shared publications Adam M. Klein
Winship Cancer Institute Emory University Atlanta Georgia USA
1 shared publicationAmy Chen
Winship Cancer Institute Emory University Atlanta Georgia USA
1 shared publicationAshley McCook‐Veal
Winship Cancer Institute Emory University Atlanta Georgia USA
1 shared publicationFadlo R. Khuri
Winship Cancer Institute Emory University Atlanta Georgia USA
1 shared publication- Jonathan J. Beitler
Winship Cancer Institute Emory University Atlanta Georgia USA
1 shared publication
Latest Publications
- 28 April 2025
- Published by Wiley in Head & Neck
- Vol. 47 (9) , 2594-2602
Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early‐Stage Squamous Cell Carcinoma of the Head and Neck: Long‐Term Follow‐Up
Background: Patients with early‐stage head and neck squamous cell carcinoma (HNSCC) have an increased risk for secondary primary tumors (SPT) after definitive treatment. The aim of this pilot trial was to investigate the safety and efficacy of erlotinib and celecoxib in preventing SPTs. Methods: Ten patients with stage I/II HNSCC who completed definitive treatment received erlotinib with celecoxib for 6 months. Primary objectives were safety assessment and SPT‐free survival after completion of erlotinib and celecoxib. Secondary objectives included assessing overall survival (OS) and progression‐free survival (PFS). Results: With a median follow‐up of 9 (1.7–15.3) years, the median time to SPT‐free survival was not reached. The estimated SPT‐free survival was 78.8% at 15 years. Two patients had local recurrence, but none of our subjects developed mucosal squamous cell carcinoma at any site. Conclusion: All three doses of erlotinib and the fixed dose of celecoxib were well tolerated with excellent SPT‐free survival with long‐term follow‐up. Trial Registration: Clinicaltrials.gov identifier: NCT00400374
- 28 April 2025
- Published by Wiley in Head & Neck
- Vol. 47 (9) , 2594-2602
Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early‐Stage Squamous Cell Carcinoma of the Head and Neck: Long‐Term Follow‐Up
Background: Patients with early‐stage head and neck squamous cell carcinoma (HNSCC) have an increased risk for secondary primary tumors (SPT) after definitive treatment. The aim of this pilot trial was to investigate the safety and efficacy of erlotinib and celecoxib in preventing SPTs. Methods: Ten patients with stage I/II HNSCC who completed definitive treatment received erlotinib with celecoxib for 6 months. Primary objectives were safety assessment and SPT‐free survival after completion of erlotinib and celecoxib. Secondary objectives included assessing overall survival (OS) and progression‐free survival (PFS). Results: With a median follow‐up of 9 (1.7–15.3) years, the median time to SPT‐free survival was not reached. The estimated SPT‐free survival was 78.8% at 15 years. Two patients had local recurrence, but none of our subjects developed mucosal squamous cell carcinoma at any site. Conclusion: All three doses of erlotinib and the fixed dose of celecoxib were well tolerated with excellent SPT‐free survival with long‐term follow‐up. Trial Registration: Clinicaltrials.gov identifier: NCT00400374
- 9 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 17 (10) , 443-455
Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives
Head and neck squamous cell carcinoma (HNSCC) is a spectrum of heterogeneous malignancies. A variety of genetic, environmental, and lifestyle factors contribute to the development of HNSCC. Carcinogenesis is a multistep process in which cell proliferation–associated oncogenes and cell-cycle regulation–associated tumor suppressor genes are dysregulated, resulting in premalignant lesions. Immune evasion is a critical step in the progression of benign lesions to advanced cancer. This review discusses the advances that have been made in chemoprevention strategies for HNSCC. The rationale for the use of chemopreventive agents to inhibit head and neck cancer development is highlighted by the positive outcomes of several clinical trials. We discuss the potential of some of the commonly studied agents including vitamin A analogs, EGFR inhibitors, COX-2 inhibitors, metabolic modulators, and natural compounds such as green tea, as well as immunotherapy and photodynamic therapy to prevent HNSCC. Our review provides insight into the potential benefits of these agents and the gaps that remain to be addressed. The published results reaffirm the promise of chemoprevention in head and neck cancer and suggest that continued exploration is needed to overcome the limitations. Because the current focus on chemopreventive agents is limited, major efforts in precision oncology approaches and substantial increase in funding will promote research into chemoprevention, which will eventually decrease the incidence of HNSCC.
- 9 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 17 (10) , 443-455
Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives
Head and neck squamous cell carcinoma (HNSCC) is a spectrum of heterogeneous malignancies. A variety of genetic, environmental, and lifestyle factors contribute to the development of HNSCC. Carcinogenesis is a multistep process in which cell proliferation–associated oncogenes and cell-cycle regulation–associated tumor suppressor genes are dysregulated, resulting in premalignant lesions. Immune evasion is a critical step in the progression of benign lesions to advanced cancer. This review discusses the advances that have been made in chemoprevention strategies for HNSCC. The rationale for the use of chemopreventive agents to inhibit head and neck cancer development is highlighted by the positive outcomes of several clinical trials. We discuss the potential of some of the commonly studied agents including vitamin A analogs, EGFR inhibitors, COX-2 inhibitors, metabolic modulators, and natural compounds such as green tea, as well as immunotherapy and photodynamic therapy to prevent HNSCC. Our review provides insight into the potential benefits of these agents and the gaps that remain to be addressed. The published results reaffirm the promise of chemoprevention in head and neck cancer and suggest that continued exploration is needed to overcome the limitations. Because the current focus on chemopreventive agents is limited, major efforts in precision oncology approaches and substantial increase in funding will promote research into chemoprevention, which will eventually decrease the incidence of HNSCC.